Li et al., 2021 - Google Patents
A novel off-the-shelf trastuzumab-armed NK cell therapy (ACE1702) using antibody-cell-conjugation technologyLi et al., 2021
View HTML- Document ID
- 6268517988453856648
- Author
- Li H
- Hsiao C
- Yang S
- Yang H
- Wu T
- Lee C
- Lin Y
- Pan J
- Cheng Z
- Lai Y
- Hsiao S
- Tang S
- Publication year
- Publication venue
- Cancers
External Links
Snippet
Simple Summary Chimeric antigen receptor T cell therapy has shown its potency against hematologic malignancies in autologous settings but also limited success against solid tumors with severe adverse events, including fatal cases of cytokine releasing syndrome …
- 210000000822 Killer Cells, Natural 0 title abstract description 55
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | A novel off-the-shelf trastuzumab-armed NK cell therapy (ACE1702) using antibody-cell-conjugation technology | |
| Klapdor et al. | Characterization of a novel third-generation anti-CD24-CAR against ovarian cancer | |
| Hambach et al. | Targeting CD38-expressing multiple myeloma and burkitt lymphoma cells in vitro with nanobody-based chimeric antigen receptors (Nb-CARs) | |
| Laborda et al. | Development of a chimeric antigen receptor targeting C-type lectin-like molecule-1 for human acute myeloid leukemia | |
| Sun et al. | Blockade of PD-L1 enhances cancer immunotherapy by regulating dendritic cell maturation and macrophage polarization | |
| Tóth et al. | A small number of HER2 redirected CAR T cells significantly improves immune response of adoptively transferred mouse lymphocytes against human breast cancer xenografts | |
| Liu et al. | Establishment and characterization of humanized mouse NPC-PDX model for testing immunotherapy | |
| Vallera et al. | A HER2 tri-specific NK cell engager mediates efficient targeting of human ovarian cancer | |
| Klapdor et al. | NK cell-mediated eradication of ovarian cancer cells with a novel chimeric antigen receptor directed against CD44 | |
| Seipel et al. | sBCMA plasma level dynamics and anti-BCMA CAR-T-cell treatment in relapsed multiple myeloma | |
| Hofmann et al. | The potential of CD16 on plasma-derived exosomes as a liquid biomarker in head and neck cancer | |
| Lee et al. | Developing ROR1 targeting CAR-T cells against solid tumors in preclinical studies | |
| Damele et al. | Cord blood-derived natural killer cell exploitation in immunotherapy protocols: more than a promise? | |
| Li et al. | Novel bispecific aptamer enhances immune cytotoxicity against MUC1-positive tumor cells by MUC1-CD16 dual targeting | |
| Van Acker et al. | CD56 homodimerization and participation in anti-tumor immune effector cell functioning: a role for interleukin-15 | |
| Voynova et al. | Increased activity of a NK-specific CAR-NK framework targeting CD3 and CD5 for T-cell leukemias | |
| Oh et al. | Cryopreserved human natural killer cells exhibit potent antitumor efficacy against orthotopic pancreatic cancer through efficient tumor-homing and cytolytic ability | |
| Makanga et al. | Genetic and molecular basis of heterogeneous NK cell responses against acute leukemia | |
| Ehlers et al. | ADCC-inducing antibody trastuzumab and selection of KIR-HLA ligand mismatched donors enhance the NK cell anti-breast cancer response | |
| Devillier et al. | Phase I trial of prophylactic donor-derived IL-2-activated NK cell infusion after allogeneic hematopoietic stem cell transplantation from a matched sibling donor | |
| Roy et al. | Folate receptor beta as a direct and indirect target for antibody-based cancer immunotherapy | |
| Klobuch et al. | HLA-DPB1 reactive T cell receptors for adoptive immunotherapy in allogeneic stem cell transplantation | |
| Gossel et al. | Retargeting of nk-92 cells against high-risk rhabdomyosarcomas by means of an erbb2 (Her2/neu)-specific chimeric antigen receptor | |
| Chen et al. | Anti-tumor activity of expanded PBMC-derived NK cells by feeder-free protocol in ovarian cancer | |
| Yekehfallah et al. | Generation and functional characterization of PLAP CAR-T cells against cervical cancer cells |